Drug intelligence / Profile preview

cefazolin sodium

Development stage: Preclinical
Lead developer: Nal Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

NAL9316 is an intravenous formulation of cefazolin sodium, a first-generation cephalosporin antibiotic being developed by NAL Pharmaceutical Group. As a beta-lactam antibiotic, it exerts its bactericidal effect by binding to and inhibiting penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This inhibition prevents the final transpeptidation step of peptidoglycan synthesis, leading to cell wall instability and osmotic lysis of the bacteria. The drug is intended for the treatment of various bacterial infections and is currently in the preclinical stage of development.

Other names: Cefazolin Sodium IVCefazolin sodium

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on cefazolin sodium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefazolin sodium.

Explore the full profile